Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

29.11.2024 11:30:00 CET | news aktuell GmbH | Press release

Share
  • Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
  • Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board
Oren Weininger, CEO Copyright Strides Pharma International AG.
Oren Weininger, CEO Copyright Strides Pharma International AG.

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.

Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.

The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.

Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”

Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.

For further information, please visit: www.fair-med.com/newsroom

Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690

Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.

Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.

Images

Oren Weininger, CEO Copyright Strides Pharma International AG.
Oren Weininger, CEO Copyright Strides Pharma International AG.
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

10 Years of the Elbphilharmonie Hamburg: Spectacular Concert Hall Celebrates Its Success Story2.9.2026 09:00:38 CEST | Press release

HAMBURG -The opening of the Elbphilharmonie Hamburg will mark its tenth anniversary on 11 January 2027. At the start of the anniversary season, the spectacular concert hall presented key figures from its success story: annual attendance at classical concerts in Hamburg has tripled since the Elbphilharmonie opened. 7.4 million people have attended around 6,400 concerts and events at the Elbphilharmonie, while 29.5 million have visited the Plaza, the public viewing platform 37 metres above ground. Ten years after opening the Elbphilharmonie has become a landmark of Hamburg and an internationally established concert venue. Its impact extends far beyond the concert hall itself: its architecture, public Plaza and a programme combining musical excellence with a spirit of discovery have transformed the perception of Hamburg as a city of music. What was once a controversial construction project has become a concert hall that inspires the people of Hamburg as much as artists, orchestras and cur

Planned Multi-Billion-Euro Investment in Infrastructure and Digitalization: Mecklenburg-Vorpommern and the Companies of Schwarz Group Form Groundbreaking Partnership27.8.2026 14:09:24 CEST | Press release

The companies of Schwarz Group aim to invest up to 5.6 billion euros by 2033 in the construction of a data center, strengthening critical infrastructure in Mecklenburg-Vorpommern. Digital Sovereignty: The investment is intended to promote the development and operation of cloud and AI solutions under German law, thereby fostering value creation in Germany and Europe. Sustainability: Plans include the exclusive use of renewable energy during regular operations, the development of a district heating network, and state-of-the-art air cooling to ensure the ecological efficiency of the data center. Blueprint for Germany: The first flagship projects of the Mecklenburg-Vorpommern state government and Schwarz Digits include a digital building permit system and the introduction of OpenDesk in the education sector.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye